#United States #New York #Rosen Law Firm #Securities Class Action #ADMA Biologics

Investor Alert: Rosen Law Firm Investigates ADMA Biologics

The Rosen Law Firm, renowned for its commitment to investor rights, has announced a significant investigation concerning potential securities claims on behalf of shareholders of ADMA Biologics, Inc. This comes in the wake of allegations suggesting that the company might have disseminated significantly misleading business information to the public.

Why this Matters

If you are a shareholder of ADMA Biologics and purchased securities recently, you may qualify for compensation at no cost through a contingency fee arrangement facilitated by the Rosen Law Firm's efforts. This investigation is crucial as the firm prepares to initiate a class action aimed at recovering losses sustained by investors.

Understanding the Current Situation

Recent reporting by Investing.com highlighted the troubling aspects surrounding ADMA Biologics, revealing potential misconduct. On March 24, 2026, the platform reported that ADMA shares plummeted following allegations from short-seller Culper Research, who claimed that the company was engaging in channel stuffing to create an illusion of revenue growth.

In direct correlation to this news, ADMA Biologics experienced a staggering 16.6% drop in its stock price on the same day, raising concerns among investors about the reliability of the company's previous communications.

What Investors Should Do

The Rosen Law Firm is urging all impacted investors to act quickly. To join the prospective class action, you can visit the following link: Join the class action. Alternatively, you can reach out directly to Phillip Kim, Esq. via their toll-free number 866-767-3653 or send an email to [email protected] for further insights regarding the class action process.

The Importance of Choosing Qualified Legal Counsel

The Rosen Law Firm implores investors to select experienced legal representation with a proven success rate in managing securities class actions. Many firms issuing similar notices might lack the necessary experience or resources to litigate effectively. Rosen Law Firm has established itself as a leading entity in the realm of investor representation globally, focusing primarily on accomplishing favorable settlements for its clients. In fact, they achieved the largest ever securities class action settlement against a Chinese company, reflecting their prowess in the field.

Since 2013, Rosen Law Firm has consistently ranked in the top four for securities class action settlements and has secured hundreds of millions of dollars for investors. Notably, in 2019 alone, the firm garnered over $438 million on behalf of affected investors, demonstrating their commitment to this cause. Furthermore, the founding partner, Laurence Rosen, was recognized by Law360 as a 'Titan of the Plaintiffs' Bar,' highlighting the firm's reputable status.

Stay Connected for Updates

Investors are encouraged to stay updated on this investigation and related news. Follow the Rosen Law Firm on LinkedIn, Twitter, and Facebook for continuous updates and guidance. Links for the social media platforms are provided: LinkedIn, Twitter, Facebook.

Conclusion

If you hold shares in ADMA Biologics, now is the time to consider your options regarding potential losses due to this recent investigation into the company's practices. Reach out to the Rosen Law Firm for guidance and representation. Remember, prior results do not guarantee a similar outcome, but with experienced counsel, you stand a better chance of seeking justice and recovery for your investments.